Cover Image

Characterization of M1A2 monoclonal antibody and in vitro cytotoxicity assessment

Despite all the big achievements in diagnosis and clinical advances, cancer as a life threatening illness, remains a problematic issue. Clinical successes of monoclonal antibodies confirm the capacity of immunotherapeutics to amend the demands in cancer treatment. To find a potential therapeutic a...

Full description

Saved in:
Bibliographic Details
Main Author: Bashokouh, Fatemeh
Format: Thesis
Language:English
Published: 2012
Online Access:http://psasir.upm.edu.my/id/eprint/48334/1/FBSB%202012%2056R.pdf
http://psasir.upm.edu.my/id/eprint/48334/
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.upm.eprints.48334
record_format eprints
spelling my.upm.eprints.483342017-01-20T04:08:51Z http://psasir.upm.edu.my/id/eprint/48334/ Characterization of M1A2 monoclonal antibody and in vitro cytotoxicity assessment Bashokouh, Fatemeh Despite all the big achievements in diagnosis and clinical advances, cancer as a life threatening illness, remains a problematic issue. Clinical successes of monoclonal antibodies confirm the capacity of immunotherapeutics to amend the demands in cancer treatment. To find a potential therapeutic and diagnostic product, several hybridoma clones were established earlier by fusion of lymphocytes from BALB/c mice sensitized with MCF7 breast carcinoma cell line and Sp20/0-Ag 14 myeloma cells. M1A2 is one of the stable hybridoma clones producing an IgM monoclonal antibody with < light chain. In this study, the M1A2 hybridoma clone was recloned by limiting dilution technique and the monoclonal antibody reactivity was screened against MCF7 and HT29 cell lines using cell-ELISA. High producer hybridoma clone was selected and the monoclonal antibody was produced in culture media (in vitro) and in ascitic fluid of peritoneal cavity of pristine primed BALB/c mice. Then the antibody was purified by an affinity chromatography on an F PLC system. The purified monoclonal antibody was characterized by immunological experiments such as immunofluorescence assay and immunohistochemistry. Then the target antigen was identified using protein techniques such as gel electrophoresis, immunoblotting and MALDI TOF/TOF mass spectrometry. Finally, the cytotoxicity potential of antibody was examined by MTT assay and complement-dependent cytotoxicity as well as antibody-dependent cellular cytotoxicity experiments. The results displayed the reactivity of M1A2 monoclonal antibody against tested human, mouse and rabbit cell lines in cell-ELISA technique. The reactivity results were further confirmed by immunofluorescence assay, which illustrated FITClabelling in cells’ cytoplasm. Immunohistochemical studies also revealed the positive staining of both human normal and cancerous tissues with M1A2 mAb with positive nuclear staining in less-differentiated carcinomas and cytoplasmic in welldifferentiated cancerous as well as normal breast, colon and ovary tissues. The flow cytometry analysis also verified the reactivity of M1A2 mAb toward both normal and cancerous cell lines. The HT29 cell line showed the highest percentage of stained cells with 90.07±1.15% followed by PBMC, HeLa and MCF7 with 88.7±0.35%, 77.3±2.66% and 52±0.76%, positive staining respectively measured by flow cytometry. Additional experiments were performed to identify M1A2 mAb target protein. A 65 kDa protein band was recognized on PVDF membrane in western blot experiment and a protein with a same molecular weight was immunoprecipitated from HT29 whole cell lysate by the M1A2 mAb. Then the m target protein was identified using MALDI TOF/TOF mass spectrometry and data mining suggested this protein belongs to heat shock protein family named Hsp60. The antibody also displays in vitro cytotoxicity toward MCF7 and PBMC with an approximate IC50 value of 403 μg/ mL. These findings support the introduction of M1A2 mAb as a new monoclonal antibody that recognize Hsp60 protein. With regard to the importance of heat shock proteins especially Hsp60 in new cancer research studies, the M1A2 mAb has the potential to develop as diagnostic and or therapeutic monoclonal antibody in future works. 2012-06 Thesis NonPeerReviewed application/pdf en http://psasir.upm.edu.my/id/eprint/48334/1/FBSB%202012%2056R.pdf Bashokouh, Fatemeh (2012) Characterization of M1A2 monoclonal antibody and in vitro cytotoxicity assessment. PhD thesis, Universiti Putra Malaysia.
institution Universiti Putra Malaysia
building UPM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Putra Malaysia
content_source UPM Institutional Repository
url_provider http://psasir.upm.edu.my/
language English
description Despite all the big achievements in diagnosis and clinical advances, cancer as a life threatening illness, remains a problematic issue. Clinical successes of monoclonal antibodies confirm the capacity of immunotherapeutics to amend the demands in cancer treatment. To find a potential therapeutic and diagnostic product, several hybridoma clones were established earlier by fusion of lymphocytes from BALB/c mice sensitized with MCF7 breast carcinoma cell line and Sp20/0-Ag 14 myeloma cells. M1A2 is one of the stable hybridoma clones producing an IgM monoclonal antibody with < light chain. In this study, the M1A2 hybridoma clone was recloned by limiting dilution technique and the monoclonal antibody reactivity was screened against MCF7 and HT29 cell lines using cell-ELISA. High producer hybridoma clone was selected and the monoclonal antibody was produced in culture media (in vitro) and in ascitic fluid of peritoneal cavity of pristine primed BALB/c mice. Then the antibody was purified by an affinity chromatography on an F PLC system. The purified monoclonal antibody was characterized by immunological experiments such as immunofluorescence assay and immunohistochemistry. Then the target antigen was identified using protein techniques such as gel electrophoresis, immunoblotting and MALDI TOF/TOF mass spectrometry. Finally, the cytotoxicity potential of antibody was examined by MTT assay and complement-dependent cytotoxicity as well as antibody-dependent cellular cytotoxicity experiments. The results displayed the reactivity of M1A2 monoclonal antibody against tested human, mouse and rabbit cell lines in cell-ELISA technique. The reactivity results were further confirmed by immunofluorescence assay, which illustrated FITClabelling in cells’ cytoplasm. Immunohistochemical studies also revealed the positive staining of both human normal and cancerous tissues with M1A2 mAb with positive nuclear staining in less-differentiated carcinomas and cytoplasmic in welldifferentiated cancerous as well as normal breast, colon and ovary tissues. The flow cytometry analysis also verified the reactivity of M1A2 mAb toward both normal and cancerous cell lines. The HT29 cell line showed the highest percentage of stained cells with 90.07±1.15% followed by PBMC, HeLa and MCF7 with 88.7±0.35%, 77.3±2.66% and 52±0.76%, positive staining respectively measured by flow cytometry. Additional experiments were performed to identify M1A2 mAb target protein. A 65 kDa protein band was recognized on PVDF membrane in western blot experiment and a protein with a same molecular weight was immunoprecipitated from HT29 whole cell lysate by the M1A2 mAb. Then the m target protein was identified using MALDI TOF/TOF mass spectrometry and data mining suggested this protein belongs to heat shock protein family named Hsp60. The antibody also displays in vitro cytotoxicity toward MCF7 and PBMC with an approximate IC50 value of 403 μg/ mL. These findings support the introduction of M1A2 mAb as a new monoclonal antibody that recognize Hsp60 protein. With regard to the importance of heat shock proteins especially Hsp60 in new cancer research studies, the M1A2 mAb has the potential to develop as diagnostic and or therapeutic monoclonal antibody in future works.
format Thesis
author Bashokouh, Fatemeh
spellingShingle Bashokouh, Fatemeh
Characterization of M1A2 monoclonal antibody and in vitro cytotoxicity assessment
author_facet Bashokouh, Fatemeh
author_sort Bashokouh, Fatemeh
title Characterization of M1A2 monoclonal antibody and in vitro cytotoxicity assessment
title_short Characterization of M1A2 monoclonal antibody and in vitro cytotoxicity assessment
title_full Characterization of M1A2 monoclonal antibody and in vitro cytotoxicity assessment
title_fullStr Characterization of M1A2 monoclonal antibody and in vitro cytotoxicity assessment
title_full_unstemmed Characterization of M1A2 monoclonal antibody and in vitro cytotoxicity assessment
title_sort characterization of m1a2 monoclonal antibody and in vitro cytotoxicity assessment
publishDate 2012
url http://psasir.upm.edu.my/id/eprint/48334/1/FBSB%202012%2056R.pdf
http://psasir.upm.edu.my/id/eprint/48334/
_version_ 1643834144797491200
score 13.211869

Similar Items